WO2013132511A1 - Nouveau polymorphe de chlorhydrate de lurasidone - Google Patents

Nouveau polymorphe de chlorhydrate de lurasidone Download PDF

Info

Publication number
WO2013132511A1
WO2013132511A1 PCT/IN2012/000548 IN2012000548W WO2013132511A1 WO 2013132511 A1 WO2013132511 A1 WO 2013132511A1 IN 2012000548 W IN2012000548 W IN 2012000548W WO 2013132511 A1 WO2013132511 A1 WO 2013132511A1
Authority
WO
WIPO (PCT)
Prior art keywords
lurasidone hydrochloride
amorphous form
solvent
mixture
lurasidone
Prior art date
Application number
PCT/IN2012/000548
Other languages
English (en)
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Itiyala Srinivas Reddy
Bandi Vamsi Krishna
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Publication of WO2013132511A1 publication Critical patent/WO2013132511A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention provides a novel amorphous Form of lurasidone hydrochloride, process for its preparation and pharmaceutical compositions comprising it.
  • Lurasidone hydrochloride is chemically, (3a/?,45',7i?,7a 1 S)-2-[((li?,2i?)-2- ⁇ [4-(l ,2- benzisothiazol-3-yl)-piperazin-l-yl]methyl ⁇ cyclohexyl)methyl]hexahydro-lH-4,7- methanisoindol-l,3-dione hydrochloride and has the structural formula:
  • Lurasidone hydrochloride is a typical antipsychotic developed by Dainippon Sumitomo Pharma under the trade name Latuda ® .
  • Polymorphism is defined as "the ability of a substance to exist as two or more crystalline phases that have different arrangement and/or conformations of the molecules in the crystal Lattice.
  • polymorphs are different crystalline structures of the same pure substance in which the molecules have different arrangements and/or different configurations of the molecules.
  • Different polymorphs may differ in their physical properties such as melting point, solubility, X-ray diffraction patterns, etc. Although those differences disappear once the compound is dissolved, they can appreciably influence pharmaceutically relevant properties of the solid form, such as handling properties, dissolution rate and stability. Such properties can significantly influence the processing, shelf life, and commercial acceptance of a polymorph.
  • Polymorphic forms of a compound can be distinguished in the laboratory by analytical methods such as X-ray diffraction (XRD), Differential Scanning Calorimetry (DSC) and Infrared spectrometry (IR).
  • XRD X-ray diffraction
  • DSC Differential Scanning Calorimetry
  • IR Infrared spectrometry
  • Solvent medium and mode of crystallization play very important role in obtaining one polymorphic Form over the other.
  • Lurasidone and its salts can exist in different polymorphic Forms, which may differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
  • lurasidone hydrochloride crystalline Form I The powdered x-ray diffractogram (PXRD) of lurasidone hydrochloride crystalline Form I is shown in figure 1. Crystalline Form I is characterized by peaks in the powder x-ray diffraction spectrum having 2 ⁇ angle positions at about 1 1.4, 13.9, 15.1, 15.5, 16.4, 17.1, 19.5, 20.8 and 21.9 ⁇ 0.2 degrees.
  • novel amorphous Form of lurasidone hydrochloride has been found to be stable, reproducible and so, suitable for pharmaceutical preparations.
  • the novel amorphous Form of lurasidone hydrochloride of the present invention is different from the prior art amorphous Form of lurasidone hydrochloride as disclosed in '246 patent, specifically in the pattern of Powdered X-Ray Diffractogram.
  • an object of the present invention is to provide a novel amorphous Form of lurasidone hydrochloride, process for its preparation and pharmaceutical compositions comprising it.
  • the present invention provides an amorphous Form of lurasidone hydrochloride.
  • the present invention provides a process for the preparation of lurasidone hydrochloride amorphous Form, which comprises:
  • the present invention provides a process for the preparation of lurasidone hydrochloride amorphous Form, which comprises:
  • the present invention provides a process for the preparation of lurasidone hydrochloride amorphous Form, which comprises:
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising amorphous Form of lurasidone hydrochloride and pharmaceutically acceptable excipients.
  • Figure 1 is an X-ray powder diffraction spectrum of lurasidone hydrochloride crystalline Form I.
  • Figure 2 is an X-ray powder diffraction spectrum of lurasidone hydrochloride amorphous Form obtained by the example 3 and example 4.
  • Figure 3 is an X-ray powder diffraction spectrum of lurasidone hydrochloride amorphous Form obtained by the example 7.
  • Figure 4 is an X-ray powder diffraction spectrum of lurasidone hydrochloride amorphous Form obtained by the example 1 1.
  • Figure 5 is an X-ray powder diffraction spectrum of lurasidone hydrochloride amorphous Form obtained by the example 13.
  • X-ray powder diffraction spectrum was measured on a bruker axs D8 advance X- ray powder diffractometer having a copper- ⁇ radiation. Approximately 500 mg of sample was gently flattered on a sample holder and scanned from 2 to 50 degrees two- theta, at 0.020 degrees two theta per step and a step time of 10.6 seconds. The sample was simply placed on the sample holder. The sample was rotated at 30 rpm at a voltage 40 KV and current 35 mA.
  • room temperature refers to temperature at about 25 to 35°C.
  • an amorphous Form of lurasidone hydrochloride there is provided an amorphous Form of lurasidone hydrochloride.
  • the powdered x-ray diffractogram (PXRD) of lurasidone hydrochloride amorphous Form is shown in figures 2, 3, 4 and 5.
  • the lurasidone hydrochloride amorphous Form obtained may have water content of up to 20.0% by weight.
  • a process for the preparation of lurasidone hydrochloride amorphous Form which comprises:
  • Lurasidone hydrochloride used in step (a) may preferably be lurasidone hydrochloride obtained by the known process.
  • the alcoholic solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, n-butanol and isobutyl alcohol. More preferably the alcoholic solvent is methanol.
  • Lyophilization refers to a sublimation process that removes free water or other solvent in the form of solid.
  • a process for the preparation of lurasidone hydrochloride amorphous Form which comprises:
  • Lurasidone hydrochloride used in step (a) may preferably be lurasidone hydrochloride obtained by the known process.
  • the alcoholic solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, n-butanol and isobutyl alcohol. More preferably the alcoholic solvent is ethanol.
  • the chlorinated solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from methylene chloride, ethylene chloride, chloroform and carbon tetrachloride, and more preferably the chlorinated solvent is methylene chloride.
  • Spray drying refers to is a method of producing a dry powder from a liquid or slurry by rapidly drying with a hot gas.
  • a process for the preparation of lurasidone hydrochloride amorphous Form which comprises:
  • Lurasidone hydrochloride used in step (a) may preferably be lurasidone hydrochloride obtained by the known process.
  • the alcoholic solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from methanol, ethanol, isopropyl alcohol, tert-butyl alcohol, n-butanol and isobutyl alcohol. More preferably the alcoholic solvent is methanol.
  • the chlorinated solvent used in step (a) may preferably be a solvent or a mixture of solvents selected from methylene chloride, ethylene chloride, chloroform and carbon tetrachloride, and more preferably the chlorinated solvent is methylene chloride.
  • the ether solvent used in step (a) may preferably be a solvent or mixture of solvents selected from tetrahydrofuran, 1 ,4-dioxane, methyl tert-butyl ether and diethyl ether, and more preferably the ether solvent is methyl tert-butyl ether.
  • the solvent may be removed from the solution in step (b) by known methods, for example, distillation.
  • the distillation of the solvent may be carried out at atmospheric pressure or at reduced pressure.
  • the distillation may preferably be carried out until the solvent is almost completely distilled off.
  • reduced pressure refers to a pressure of less than 100 mmHg.
  • a pharmaceutical composition comprising amorphous Form of lurasidone hydrochloride and pharmaceutically acceptable excipients, and optionally other therapeutic ingredients.
  • the amorphous Form may preferably be formulated into tablets, capsules, suspensions, dispersions, injectables or other pharmaceutical forms.
  • Trans- l ,2-bis(hydroxymethyl)cyclohexane 50 gm was dissolved in methylene chloride (1000 ml) and then added triethylamine (136 ml). The contents were then cooled to 0°C and then added methylsulfonyl chloride (51 ml) slowly at 0 to 5°C. The temperature of the reaction mass was raised to room temperature and stirred for 16 hours. Water (500 ml) was added to the reaction mass and stirred for 15 minutes at room temperature. The layers were separated and the aqueous layer was extracted with methylene chloride. Combined organic layers were dried with sodium sulfate and then concentrated to obtain a residual solid.
  • Acetonitrile 300 ml was added to trans-1 ,2- bis(methanesulfonyloxymethyl)cyclohexane (20 gm) under stirring at room temperature.
  • a mixture of l-(l ,2-benzoisothiazol-3-yl)-piperazine (13.2 gm), sodium carbonate (6.6 gm) and tetrabutyiammonium hydrogen sulfate (200 mg) was added to the solution under stirring.
  • the temperature of the reaction mass was raised to 85°C and then heated to reflux.
  • the reaction mass was maintained for 48 hours at reflux and then cooled to 70°C.
  • the reaction mass was filtered and then concentrated to obtain a residual solid.
  • Toluene (225 ml) was added to trans-3a,7a-octahydroisoindolium-2-spiro-T-[4'- (l,2-benisothiazol-3-yl)]piperazine methane sulfonate (15 gm) and then added potassium carbonate (7.5 gm) under stirring.
  • To the reaction mixture was added bicyclo[2.2.1]heptane-2-exo-3-exo-dicarboximide (10 gm) and 18-crown ether (1.1 gm). The contents were heated to reflux and maintained for 4 hours.
  • To the reaction mass was added water (500 ml) and then the separated aqueous layer was extracted with toluene.
  • Lurasidone (4 gm) as obtained in example 1 was dissolved in acetone (200 ml) and stirred for 30 minutes at room temperature to obtain a clear solution. To the solution was added a solution of hydrochloric acid in isopropyl alcohol (4 ml) slowly and then cooled to 0 to 5°C. The contents were maintained for 1 hour at 0 to 5°C and filtered. The solid obtained was dried at 50°C under vacuum for 6 hours to give 3 gm of lurasidone hydrochloride crystalline Form I.
  • Example 3 Example 3:
  • Lurasidone hydrochloride crystalline Form 1 (2.5 gm) as obtained in example 2 was dissolved in methanol (169 ml) and water (955 ml) under stirring. The solution was treated with activated carbon and filtered. The filtrate thus obtained containing 15% of methanol and 85% of water was lyophilized at room temperature for 24 hours to obtain 2.5 gm of lurasidone hydrochloride amorphous Form.
  • Lurasidone hydrochloride (10 gm) was dissolved in methanol (675 ml) and water (3800 ml) under stirring. The solution was treated with activated carbon and filtered. The filtrate thus obtained containing 15% of methanol and 85% of water was lyophilized at room temperature for 24 hours to obtain 9.8 gm of lurasidone hydrochloride amorphous Form.
  • Example 3 was repeated using ethanol solvent instead of methanol solvent to obtain lurasidone hydrochloride amorphous Form.
  • Example 3 was repeated using n-butanol solvent instead of methanol solvent to obtain lurasidone hydrochloride amorphous Form.
  • Example 7 was repeated using n-butanol solvent instead of methanol solvent to obtain lurasidone hydrochloride amorphous Form.
  • Lurasidone hydrochloride (10 gm) was dissolved in ethanol (125 ml) and methylene dichloride (125 ml) at room temperature. The solution was treated with carbon and filtered through hi-flow bed. The resulting filtrate was subjected to spray drying at 60 to 65°C to obtain 9.5 gm of lurasidone hydrochloride amorphous Form.
  • Example 7 was repeated using methanol solvent instead of ethanol solvent to obtain lurasidone hydrochloride amorphous Form.
  • Example 7 was repeated using n-butanol solvent instead of ethanol solvent to obtain lurasidone hydrochloride amorphous Form.
  • Example 7 was repeated using ethylene chloride solvent instead of methylene chloride solvent to obtain lurasidone hydrochloride amorphous Form.
  • Lurasidone hydrochloride (10 gm) was dissolved in methanol (675 ml) under stirring at room temperature to obtain a clear solution. The solution was treated with carbon and filtered through hi-flow bed. The resulting filtrate was subjected to spray drying at 60 to 65°C to obtain 9.5 gm of lurasidone hydrochloride amorphous Form.
  • Example 11 was repeated using ethanol solvent instead of methanol solvent to obtain lurasidone hydrochloride amorphous Form.
  • Example 13 was repeated using ethylene chloride solvent instead of methylene chloride solvent to obtain lurasidone hydrochloride amorphous Form.
  • Example 13 was repeated using 1,4-dioxane solvent instead of methyl tert-butyl ether solvent to obtain lurasidone hydrochloride amorphous Form.
  • Example 13 was repeated using ethanol solvent instead of methanol solvent to obtain lurasidone hydrochloride amorphous Form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une nouvelle forme amorphe de chlorhydrate de lurasidone, son procédé de préparation et les compositions pharmaceutiques la comprenant. Selon un aspect, l'invention propose une forme amorphe de chlorhydrate de lurasidone. Selon un autre aspect, l'invention propose un procédé de préparation de la forme amorphe de chlorhydrate de lurasidone, qui comprend les étapes consistant à : a) dissoudre le chlorhydrate de lurasidone dans un mélange de solvant alcoolique et d'eau ; et b) soumettre la solution résultante à la lyophilisation afin d'obtenir la forme amorphe de chlorhydrate de lurasidone.
PCT/IN2012/000548 2012-03-09 2012-08-10 Nouveau polymorphe de chlorhydrate de lurasidone WO2013132511A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN893CH2012 2012-03-09
IN893/CHE/2012 2012-03-09

Publications (1)

Publication Number Publication Date
WO2013132511A1 true WO2013132511A1 (fr) 2013-09-12

Family

ID=49116043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000548 WO2013132511A1 (fr) 2012-03-09 2012-08-10 Nouveau polymorphe de chlorhydrate de lurasidone

Country Status (1)

Country Link
WO (1) WO2013132511A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104059061A (zh) * 2014-07-04 2014-09-24 中国药科大学 一种难溶性药物的共无定形物
ITMI20131737A1 (it) * 2013-10-17 2015-04-18 Procos Spa Processo per la sintesi industriale di lurasidone
CN106512011A (zh) * 2016-11-04 2017-03-22 中国药科大学 一种缓慢释放药物的方法
EP3207041A4 (fr) * 2014-10-14 2018-09-26 Jubilant Generics Limited (Formerly Jubilant Life Sciences Division) Procédé amélioré de préparation de chlorhydrate de lurasidone
CN110003195A (zh) * 2019-05-21 2019-07-12 湖北中医药大学 鲁拉西酮晶体及其制备方法和在注射给药系统中的应用
CN111366645A (zh) * 2018-12-26 2020-07-03 上海科胜药物研发有限公司 一种鲁拉西酮中氯乙烷含量的测定分析方法
WO2021107967A1 (fr) * 2019-01-10 2021-06-03 Slayback Pharma Llc Compositions pharmaceutiques de lurasidone
CN113024535A (zh) * 2019-12-24 2021-06-25 上海科胜药物研发有限公司 一种鲁拉西酮盐酸盐的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254223A1 (en) * 2001-08-03 2004-12-16 Yatendra Kumar Process for the preparation of amorphous form of torsemide
US20060004207A1 (en) * 2003-01-30 2006-01-05 Ljubomir Antoncic Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods
WO2006109324A2 (fr) * 2005-04-13 2006-10-19 Lupin Limited Procedes de preparation de sels d'addition acides de cefepime amorphes
US20100093875A1 (en) * 2006-10-25 2010-04-15 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation prevented from caking
WO2012063246A1 (fr) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Forme amorphe du chlorhydrate de lurasidone

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254223A1 (en) * 2001-08-03 2004-12-16 Yatendra Kumar Process for the preparation of amorphous form of torsemide
US20060004207A1 (en) * 2003-01-30 2006-01-05 Ljubomir Antoncic Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods
WO2006109324A2 (fr) * 2005-04-13 2006-10-19 Lupin Limited Procedes de preparation de sels d'addition acides de cefepime amorphes
US20100093875A1 (en) * 2006-10-25 2010-04-15 Dainippon Sumitomo Pharma Co., Ltd. Granular preparation prevented from caking
WO2012063246A1 (fr) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Forme amorphe du chlorhydrate de lurasidone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATTERSON ET AL.: "The Influence of Thermal and Mechanical Preparative Techniques on the Amorphous state of Four Poorly Soluble Compounds", J. PHARM SCI., vol. 94, no. 9, 2005, pages 1998 - 2012, XP055111748, DOI: doi:10.1002/jps.20424 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131737A1 (it) * 2013-10-17 2015-04-18 Procos Spa Processo per la sintesi industriale di lurasidone
WO2015056205A1 (fr) * 2013-10-17 2015-04-23 Procos S.P.A. Procédé pour la synthèse industrielle de lurasidone
US9518047B2 (en) 2013-10-17 2016-12-13 Procos S.P.A. Process for the industrial synthesis of lurasidone
CN104059061A (zh) * 2014-07-04 2014-09-24 中国药科大学 一种难溶性药物的共无定形物
EP3207041A4 (fr) * 2014-10-14 2018-09-26 Jubilant Generics Limited (Formerly Jubilant Life Sciences Division) Procédé amélioré de préparation de chlorhydrate de lurasidone
CN106512011A (zh) * 2016-11-04 2017-03-22 中国药科大学 一种缓慢释放药物的方法
CN111366645A (zh) * 2018-12-26 2020-07-03 上海科胜药物研发有限公司 一种鲁拉西酮中氯乙烷含量的测定分析方法
WO2021107967A1 (fr) * 2019-01-10 2021-06-03 Slayback Pharma Llc Compositions pharmaceutiques de lurasidone
US11103503B2 (en) 2019-01-10 2021-08-31 Slayback Pharma Llc Pharmaceutical compositions of Lurasidone
US11103502B2 (en) 2019-01-10 2021-08-31 Slayback Pharma Llc Pharmaceutical compositions of lurasidone
CN110003195B (zh) * 2019-05-21 2020-05-26 湖北中医药大学 鲁拉西酮晶体及其制备方法和在注射给药系统中的应用
CN110003195A (zh) * 2019-05-21 2019-07-12 湖北中医药大学 鲁拉西酮晶体及其制备方法和在注射给药系统中的应用
CN113024535A (zh) * 2019-12-24 2021-06-25 上海科胜药物研发有限公司 一种鲁拉西酮盐酸盐的制备方法
CN114728952A (zh) * 2019-12-24 2022-07-08 浙江华海药业股份有限公司 一种鲁拉西酮盐酸盐的制备方法

Similar Documents

Publication Publication Date Title
WO2013132511A1 (fr) Nouveau polymorphe de chlorhydrate de lurasidone
WO2011095059A1 (fr) Polymorphes du dasatinib, leurs procédés de préparation et leurs compositions pharmaceutiques
WO2014076712A2 (fr) Dispersion solide de chlorhydrate de lurasidone
KR20170057441A (ko) Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법
US9624207B2 (en) Polymorphs of azilsartan medoxomil
WO2019003249A1 (fr) Formes polymorphes de baricitinib
WO2007109799A2 (fr) Polymorphes de malate d'eszopiclone
US20130131090A1 (en) Salts of lapatinib
WO2018078392A1 (fr) Polymorphes de dasatinib
KR20180003542A (ko) 아파티닙과 그 염의 다형체 및 퀴나졸린일 유도체 제조 방법
EP2646457A1 (fr) Synthèse optimisée d'acides biliaires cristallins purs et non polymorphes ayant une taille définie de particule
WO2013150544A2 (fr) Dispersion solide de chlorhydrate d'ivabradine
US20140112992A1 (en) Process for febuxostat
US20130137868A1 (en) Salts of raltegravir
WO2012164575A2 (fr) Ritonavir amorphe co-précipité
EP2393786B1 (fr) Nouveaux polymorphes du lopinavir
WO2014195977A2 (fr) Nouveaux polymorphes de vismodegib
US20130190368A1 (en) Novel polymorphs of febuxostat
WO2016157136A1 (fr) Formes cristallines de l'idélalisib
WO2014013505A2 (fr) Vildagliptine amorphe
WO2014013511A2 (fr) Dispersion solide de rufinamide
WO2012046245A1 (fr) Nouvelle forme polymorphe du lacosamide
WO2022224269A1 (fr) Co-cristaux, sels et formes solides de niraparib
US9381199B2 (en) Linagliptin solid dispersion
CA2829186A1 (fr) Forme amorphe d'un melange de lopinavir et de ritonavir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12870560

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12870560

Country of ref document: EP

Kind code of ref document: A1